Article
Caelyx 20 mg/m2 q2wks in platinum-refractory or early recurrent ovarian or peritoneal cancer - results from a phase II study
Search Medline for
Authors
Published: | March 20, 2006 |
---|
Outline
Text
In this mono-institutional phase II study we investigated liposomal doxorubicin (Caelyx) 20mg/m² every two weeks in patients with ovarian or peritoneal cancer who failed a platinum based therapy or had an early recurrent disease (recurrence within six months after platinum-based therapy). Response and toxicity were evaluated especially with regard to frequency and grade of palmar-plantar erythrodysesthesia (PPE) of liposomal doxorubicin administered in a 2-week schedule. 37 patients (age 38-78) were treated. The median number of prior chemotherapy regimens was 3,1 (range 1 - 6). 14 objective responses (37.8%) were observed (3 complete and 11 partial responses). 6 patients received a stable disease. There was no hematological toxicity > G2 and only 3 G3-nonhematological toxicities. In four patients a PPE grade 2 was observed; no PPE grade 3/4 occured. Caelyx is a favourable therapeutic option in patients with platinum-refractory or early recurrent ovarian or peritoneal cancer with tolerable toxicity. In comparison with other phase II trials we found a very high response rate using Caelyx in this two-week schedule.